Research Articles | Page 15 | Aplastic Anemia and MDS International Foundation (AAMDSIF) Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
How I Treat Paroxysmal nocturnal hemoglobinuria Jan 2021 Blood Paroxysmal Nocturnal Hemoglobinuria (PNH)
Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities Mar 2020 Clinical Lymphoma , Myeloma & Leukemia Myelodysplastic Syndromes (MDS)
Hypomethylating agents are associated with high rates of hematologic toxicity in patients with secondary myeloid neoplasms developing after acquired aplastic anemia Apr 2024 Haematologica Aplastic Anemia
Idiopathic aplastic anemia vs hypocellular myelodysplastic syndrome Dec 2019 Hematology. American Society of Hematology. Education Program Aplastic Anemia
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Jan 2020 Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Oct 2020 Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Imetelstat Achieves Meaningful and Durable Transfusion Independence in High Transfusion-Burden Patients With Lower-Risk Myelodysplastic Syndromes in a Phase II Study Jan 2021 Journal of clinical oncology: official journal of the American Society Clinical Oncology Myelodysplastic Syndromes (MDS)
Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial Jan 2024 Lancet Myelodysplastic Syndromes (MDS)
Immunomodulation With Pomalidomide at Early Lymphocyte Recovery After Induction Chemotherapy in Newly Diagnosed AML and High-Risk MDS Jun 2020 Leukemia Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Immunosuppression and Growth Factors for Severe Aplastic Anemia: New Data for Old Questions May 2020 Haematologica Aplastic Anemia